Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT A WOLFF and JAMES C YAO.
ROBERT A WOLFF
Connection Strength
0.964
JAMES C YAO
  1. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80.
    View in: PubMed
    Score: 0.137
  2. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
    View in: PubMed
    Score: 0.105
  3. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
    View in: PubMed
    Score: 0.082
  4. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
    View in: PubMed
    Score: 0.063
  5. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist. 2024 Jul 16.
    View in: PubMed
    Score: 0.062
  6. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
    View in: PubMed
    Score: 0.055
  7. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022; 12:986305.
    View in: PubMed
    Score: 0.054
  8. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.052
  9. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
    View in: PubMed
    Score: 0.051
  10. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
    View in: PubMed
    Score: 0.050
  11. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766.
    View in: PubMed
    Score: 0.049
  12. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.047
  13. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
    View in: PubMed
    Score: 0.044
  14. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.039
  15. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457.
    View in: PubMed
    Score: 0.038
  16. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.